RPP1 Antibody

Introduction to RPP1 Antibodies

RPP1 antibodies are specialized tools used to detect and study RPP1 proteins, which play critical roles in diverse biological systems. Two primary contexts dominate RPP1 research:

• Plant immunity: Arabidopsis thaliana RPP1 is a nucleotide-binding leucine-rich repeat (NLR) protein that recognizes pathogen effectors to activate immune responses .

• RNA processing: In Saccharomyces cerevisiae, Rpp1 is an essential subunit of nuclear RNase P, required for tRNA and rRNA maturation .

Antibodies targeting RPP1 enable mechanistic studies through techniques like co-immunoprecipitation (Co-IP), Western blotting, and functional assays.

Structure and Functional Domains

RPP1 contains three key domains:

1. TIR (Toll/Interleukin-1 Receptor): Mediates cell death signaling .

2. NB-ARC (Nucleotide-Binding Apaf-1/R gene/CED-4): Facilitates oligomerization and activation .

3. LRR (Leucine-Rich Repeat): Directly binds effector proteins like ATR1 .

Key Research Findings

Mechanistic Insights

• Effector recognition by RPP1 triggers a conformational change, enabling TIR-mediated signaling and NB-ARC-LRR oligomerization .

• Mutations in the NB-ARC oligomerization interface (e.g., K299L) disrupt immune signaling without affecting ATR1 binding .

Role in RNase P Complex

Rpp1 is a conserved protein subunit of nuclear RNase P, essential for:

• tRNA 5′ and 3′ end processing .

• rRNA maturation, including cleavage at the A3 site in the ITS1 region .

Antibody Applications in Yeast Studies

Regulatory Insights

• Rpp1 stabilizes RNase P and MRP RNAs; its depletion reduces mature RPR1 and NME1 levels .

• Rpp1 interacts with Pop1, Pop3, and Pop4 proteins, forming a complex critical for RNA processing .

Cross-Organism Comparative Analysis

Future Directions and Challenges

• Plant studies: Elucidate structural determinants of RPP1-ATR1 binding specificity and NLR activation mechanisms .

• Yeast studies: Resolve atomic-level architecture of RNase P complexes involving Rpp1 .

• Technical advances: Develop monoclonal RPP1 antibodies for high-resolution imaging and in vivo tracking.